Korro Bio (KRRO) Construction in Progress (2022 - 2024)
Korro Bio's (KRRO) quarterly Construction in Progress came in at $18.3 million in Q2 2024, up 36.57% quarter-over-quarter from $13.4 million in Q1 2024.
Analysis
Korro Bio (KRRO) Construction in Progress (2022 - 2024) Analysis & Trends
Korro Bio (KRRO) has reported Construction in Progress for 3 consecutive years, with $18.3 million the latest figure, recorded in Q2 2024.
- For the quarter ending Q2 2024, Construction in Progress changed N/A year-over-year to $18.3 million; the trailing twelve-month figure through Jun 2024 stood at $18.3 million (changed N/A YoY), and the FY2023 full-year result was $8.2 million, up 310.0% from the prior year.
- Construction in Progress grew to $18.3 million in Q2 2024 per KRRO's latest filing, from $13.4 million in the prior quarter.
- Across five years, Construction in Progress topped out at $18.3 million in Q2 2024 and bottomed at $2.0 million in Q4 2022.
- Historically, Construction in Progress has averaged $10.5 million across 3 years, with a median of $10.8 million in 2023.
- The widest YoY moves for Construction in Progress: up 310.0% in 2023, down 310.0% in 2023.
- Over 3 years, Construction in Progress stood at $2.0 million in 2022, then surged by 310.0% to $8.2 million in 2023, then soared by 123.17% to $18.3 million in 2024.
- According to Business Quant data, Construction in Progress over the past three periods registered $18.3 million, $13.4 million, and $8.2 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Korro Bio | 231.15 Mn | 116.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 18.30 Mn |
| Mar 31, 2024 | 13.40 Mn |
| Dec 31, 2023 | 8.20 Mn |
| Dec 31, 2022 | 2.00 Mn |